Autologous peripheral blood progenitor cell transplantation with <2×106 CD34+/kg: an analysis of variables concerning mobilisation and engraftment

Abstract

Although mobilisation schedules and disease status influenced not only the yield of progenitor cells, but also the engraftment kinetics, the number of CD34(+) re-infused was the main predictor of haematopoietic recovery. While engraftment succeeded in most of the cases, the re-infusion of >2 x 10(6)/CD34(+)/kg resulted in significantly shorter recovery times.

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience

“…[1][2][3] Current data suggest that greater than 2.0 Â 10 6 CD34 þ cells/kg are needed to assure reliable and sustained hematopoietic recovery after auto-SCT. [4][5][6] Failure to transplant a sufficient number of hematopoietic stem cells can lead to delayed engraftment or graft failure. PBSCs are collected through apheresis after treatment with chemomobilization with cytokine support, usually G-CSF, or with mobilization using cytokine alone.…”

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

“…At suboptimal HPC doses, hematopoietic recovery becomes unacceptably delayed or incomplete. [1][2][3][4][5][6][7][8][9][10][11][12][13][14] As a consequence, many transplantation centers establish a minimal cell dose, often 1 to 2 ϫ 10 6 CD34 cells/kg, as a limiting dose below which they will not proceed to transplantation.…”

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

“…8,9 On the contrary, a dose of o2 million CD34 þ cells per kg is insufficient to ensure rapid and sustained hematopoietic engraftment. [10][11][12] With conventional mobilization methods, a significant proportion of auto-SCT candidates fail to collect the minimum X2 Â 10 6 per kg normally required to proceed to high-dose therapy. 8,[13][14][15] Such mobilization failures leave 5-30% of eligible patients facing further mobilization attempts, BM collections or even suboptimal alternative treatment strategies in the absence of sufficient autologous PBSCs.…”